Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

NCT05936229 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT05936229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05936229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Withdrawn
Start date
April 1, 2025
Completion date
October 30, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b acute lymphoblastic leukemia, recurrent b-cell non-hodgkin lymphoma, recurrent mantle cell lymphoma, refractory b acute lymphoblastic leukemia, refractory b-cell non-hodgkin lymphoma, refractory mantle cell lymphoma